Vericel Corporation
 (VCEL)

- NASDAQ
What's your position on ?
Bullish
Bearish
Why are you ish?
Skip
Post
You voted ish on Vote again
Posts appear on the My Feed page of subscribers to this ticker
Last vote:
  • Dec. 18, 2015, 12:46 PM
    | Dec. 18, 2015, 12:46 PM | 5 Comments
  • Nov. 13, 2015, 7:30 AM
    • Vericel (NASDAQ:VCEL): Q3 EPS of -$0.26 misses by $0.01.
    • Revenue of $11.31M (+17.1% Y/Y) beats by $0.81M.
    | Nov. 13, 2015, 7:30 AM
  • Sep. 29, 2015, 12:41 PM
    | Sep. 29, 2015, 12:41 PM
  • Aug. 12, 2015, 9:42 AM
    • Vericel (VCEL +1.5%) Q2 results: Revenues: $13.6M (+209.1%); COGS: $6.9M (+38.0%); R&D Expense: $3.4M (-22.7%); SG&A: $5.6M (+55.6%); Operating Loss: ($2.3M) (+72.9%); Net Loss: ($2.2M) (+52.2%); Loss Per Share: ($0.16) (+83.0%); Quick Assets: $129.9M (+10.1%).
    • No guidance given.
    | Aug. 12, 2015, 9:42 AM
  • Aug. 12, 2015, 7:35 AM
    • Vericel (NASDAQ:VCEL): Q2 EPS of -$0.16 beats by $0.05.
    • Revenue of $13.6M (+207.0% Y/Y) beats by $2.29M.
    | Aug. 12, 2015, 7:35 AM
  • Jun. 10, 2015, 9:55 AM
    • Following discussions with the FDA, Vericel (VCEL +1.9%) intends to submit a Biologics License Application (BLA) to the FDA by the end of this year seeking clearance for the use of MACI (matrix-applied characterized autologous cultured chondrocytes) for the treatment of chondral cartilage defects in the knee.
    • MACI is a third-generation autologous chondrocyte implantation product for the treatment of cartilage defects in the knee. Chondrocytes are cells found in healthy cartilage that maintain the cartilaginous matrix, mainly collagen and proteoglycans.
    • Cartilage problems in the knee affect millions of people, especially among athletes. Meniscal tears are the most common.
    | Jun. 10, 2015, 9:55 AM | 1 Comment
  • May 15, 2015, 9:00 AM
    • Vericel (VCEL +1.9%)  Q1 results : Revenues: $10.8M; COGS: $5.6M; R&D Expense: $4.4M (+33.3%); SG&A: $5.5M (+292.9%); Operating Loss: ($4.6M) (+1.7%); Net Loss: ($4.9M) (+18.3%); Loss Per Share: ($0.27) (+78.6%); Quick Assets: $25.9M (-14.5%).
    • No guidance given.
    | May 15, 2015, 9:00 AM
  • May 14, 2015, 4:13 PM
    • Vericel (NASDAQ:VCEL): Q1 EPS of -$0.27 misses by $0.06.
    • Revenue of $10.8M misses by $0.33M.
    | May 14, 2015, 4:13 PM
  • Mar. 24, 2015, 9:18 AM
    | Mar. 24, 2015, 9:18 AM | 3 Comments
  • Mar. 24, 2015, 6:20 AM
    • Vericel (VCEL -2.1%) Q4 results: Revenues: $14.7M (+999%); COGS: $6.8M (+999%); R&D Expense: $5.8M (+75.8%); SG&A: $4.5M (+181.3%); Operating Loss: ($2.3M) (+53.1%); Net Loss: ($2.4M) (+17.2%); Loss Per Share: ($0.17) (+82.5%).
    • FY2014 results: Revenues: $28.8M (+999%); COGS: $17.3M (+999%); R&D Expense: $21.3M (+41.1%); SG&A: $13.8M (+133.9%); Operating Loss: ($23.5M) (-11.9%); Net Loss: ($19.9M) (-27.6%); Loss Per Share: ($2.23) (+67.9%); Quick Assets: $30.3M (+274.1%).
    • No guidance given.
    | Mar. 24, 2015, 6:20 AM
  • Mar. 23, 2015, 4:04 PM
    • Vericel (NASDAQ:VCEL): Q4 EPS of -$0.17 may not be comparable to consensus of -$0.47.
    • Revenue of $14.7M beats by $4M.
    | Mar. 23, 2015, 4:04 PM
  • Nov. 13, 2014, 9:47 AM
    • Aastrom Biosciences (ASTM +3.4%) Q3 results: Revenues: $9.7M; COGS: $5.5M; R&D Expense: $7.8M (+200.0%); SG&A: $4.3M (+290.9%); Operating Loss: ($8M) (-122.2%); Net Loss: ($6.9M) (-200.0%); Loss Per Share: ($0.82) (+31.7%); Quick Assets: $37.6M (+364.2%).
    • No guidance given.
    | Nov. 13, 2014, 9:47 AM
  • Nov. 13, 2014, 8:21 AM
    • Aastrom Biosciences (NASDAQ:ASTM): Q3 EPS of -$0.52 beats by $0.14.
    • Revenue of $9.66M beats by $2.93M.
    | Nov. 13, 2014, 8:21 AM
  • Nov. 5, 2014, 5:13 PM
    • Aastrom Biosciences (NASDAQ:ASTM) will report Q3 results on November 13 before the open. The conference call will begin at 8:30 am ET.
    • Consensus view is a loss of ($0.66) per share on revenues of $6.7M.
    | Nov. 5, 2014, 5:13 PM
  • Oct. 10, 2014, 8:21 AM
    • Aastrom Biosciences (NASDAQ:ASTM) plans to change its name to Vericel Corporation and move its corporate base from Michigan to Cambridge, MA. The name change is contingent on shareholder approval.
    • President & CEO Nick Colangelo says, "The proposed name change and plan to move our headquarters to Cambridge are the next steps in the transformation of Aastrom from a clinical-stage company to a fully integrated commercial-stage specialty biologics company. The new corporate name reflects our leading position in the cell therapy market. Our expanded presence in the vibrant Cambridge biotechnology community will increase our access to both talent and technology as we continue to grow our company, maximize the potential of our two U.S.-marketed products, Carticel and Epicel, and bring our late-stage product candidates, MACI and ixmyelocel-T, to market."
    | Oct. 10, 2014, 8:21 AM
  • Sep. 11, 2014, 9:22 AM
    • Aastrom Biosciences (NASDAQ:ASTM) prices its public offering of 13,725,490 common shares at $2.55 per share. Underwriters over-allotment is 2,058,823 shares. Closing date is September 16, 2014.
    • Net proceeds will support the company's commercialization activities and fund the Phase 2b ixCELL-DCM clinical trial of ixmyelocel-T for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy in addition to general corporate purposes.
    | Sep. 11, 2014, 9:22 AM | 4 Comments
Company Description
Vericel Corp is engaged in the development of patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets two cell therapy products including Carticel and Epicel.
Sector: Healthcare
Industry: Biotechnology
Country: United States